Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized parenteral nutrition (P-PN) is a tailored intravenous nutritional therapy used in the management of preterm infants. In the context of the Phase IV clinical trial conducted by Ospedali Riuniti Ancona (NCT03693287), P-PN involves the individual prescription and pharmacy-compounding of essential nutrients to meet the specific metabolic and growth requirements of infants with a birth weight greater than 1250 grams. The formulation typically includes dextrose 50% as a glucose source, Primene as an amino acid source, and Clinoleic as a lipid emulsion. This personalized approach is compared against standardized, ready-to-use multi-chamber bag formulations (such as Numeta G13%E) to evaluate its impact on neonatal growth and nutritional outcomes. The therapy provides essential macronutrients and micronutrients directly into the bloodstream when enteral feeding is insufficient or contraindicated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on personalized parenteral nutrition (Ospedali Riuniti Ancona).